Señales en vivo de OBI.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 08:09):

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally...

Stats
Volumen de hoy	96 646.00
Volumen promedio	308 867
Capitalización de mercado	11.21M
EPS	£-0.124 ( 2011-06-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.960
ATR14	£0.244 (4.24%)

Ondine Biomedical Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ondine Biomedical Inc. Finanzas

Annual	2022
Ingresos:	£638 000
Beneficio Bruto:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2022
Ingresos:	£638 000
Beneficio Bruto:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2021
Ingresos:	£2.57M
Beneficio Bruto:	£1.25M (48.81 %)
EPS:	£-0.257

FY	2020
Ingresos:	£1.79M
Beneficio Bruto:	£649 000 (36.24 %)
EPS:	£-0.0833

Financial Reports:

No articles found.

Ondine Biomedical Inc.

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.